Description

Although there are approximately 27 drugs on the market indicated for the treatment of breast cancer, there is still an unmet need to treat patients in this market. As a result, the breast cancer pharmaceutical pipeline remains strong. This research service presents a marketed and pipeline analysis of the breast cancer therapeutics market in the United States. It highlights the current market landscape and provides a competitive analysis of all marketed and pipeline drugs. Estimated patent expirations and launch timelines as well as late-stage clinical trial overviews are provided.